Show Summary Details
Page of

(p. 296) Pharmacotherapy of Addictive Disorders 

(p. 296) Pharmacotherapy of Addictive Disorders
Chapter:
(p. 296) Pharmacotherapy of Addictive Disorders
Author(s):

Ece Tek

and Stephanie S. O’Malley

DOI:
10.1093/med:psych/9780199738168.003.0045
Page of

PRINTED FROM OXFORD CLINICAL PSYCHOLOGY ONLINE (www.oxfordclinicalpsych.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Clinical Psychology Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 October 2020

This chapter provides a brief review of medications that are currently approved by the Food and Drug Administration (FDA) for the treatment of substance use disorders (SUDs) and medications under investigation for alcohol (benzodiazepines, disulfiram, naltrexone, acamprosate), nicotine (varencline, bupropion), opiates (methadone, buprenorphine, naltrexone), stimulants, and marijuana. Information about dosing, adverse events, and contraindications are presented briefly in tables, but the reader should refer to the product information on each medication for complete information.

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.